分享产品介绍 评论(0)
物种
Mouse分子别名
Tumor necrosis factor ligand superfamily member 15,TNF ligand-related molecule 1,Vascular endothelial cell growth inhibitor,TL1AAccession
Q5UBV8表达序列
Ala61-Leu252, with N-terminal His Tag
表达宿主
HEK293分子量
27-32 kDa (Reducing)
纯度
>95% by SDS-PAGE.内毒素含量
<0.1EU/μg活性
EC50 < 30ng/ml标记
Unconjugated标签
His Tag性状
Lyophilized Powder缓冲体系
PBS, pH7.4
溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
·12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
·3 months, -20 to -80℃ under sterile conditions after reconstitution.
·1 week, 2 to 8℃ under sterile conditions after reconstitution.
·Please avoid repeated freeze-thaw cycles.文献引用
1. Cell Mol Gastroenterol Hepatol. 2020 Aug 19;11(1):249–272.
2. Cell Mol Gastroenterol Hepatol. 2021;11(1):249-272.
TNFSF15 (Tumor Necrosis Factor Superfamily Member 15), also known as TL1A, VEGI, or TNF-like ligand 1A, is a cytokine primarily produced by vascular endothelial cells. It is a member of the TNF superfamily and plays a significant role in various immune responses and inflammatory processes. TNFSF15 has been implicated in the regulation of T cell activation, dendritic cell maturation, and macrophage function.
Additionally, it is known to inhibit angiogenesis and modulate the balance of M1/M2 macrophage populations in the tumor microenvironment, which is associated with anti-tumor effects. In lung cancer, higher levels of TNFSF15 have been linked to better clinical outcomes.
TNFSF15 inhibitors or agonists could be developed to target specific pathways involved in inflammation and cancer progression. These drugs could potentially be used to treat conditions where TNFSF15 activity is dysregulated.
生物活性
Measured by its ability to induce apoptosis of TF‑1 human erythroleukemic cells in the presence of the cyclohexamide. The EC50 for this effect is less than 30ng/ml.
电泳
2μg (R: reducing condition, N: non-reducing condition).
评论(0)